Literature DB >> 9696311

125I-labeled fasciculin 2: a new tool for quantitation of acetylcholinesterase densities at synaptic sites by EM-autoradiography.

L Anglister1, J Eichler, M Szabo, B Haesaert, M M Salpeter.   

Abstract

Radio-iodinated fasciculin 2 (Fas2), a polypeptide anticholinesterase toxin from Mamba venom, was used as a new probe for localizing and quantifying acetylcholinesterase (AChE) at mouse neuromuscular junctions (NMJs) by quantitative electron microscope autoradiography. We demonstrate that 125I-Fas2 binds very specifically to the NMJs of mouse sternomastoid muscles, with very little binding to other regions in the muscles. Junctional AChE-site densities obtained from the autoradiograms were similar to those previously obtained for the same muscles using 3H-DFP. The use of 125I-Fas2 with EM-autoradiography is simpler and provides higher resolution and sensitivity, as well as considerably lower non-specific binding than previously attainable with 3H-DFP. The advantages and limitations of this procedure are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696311     DOI: 10.1016/s0165-0270(98)00015-6

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  12 in total

1.  Substrate selectivity of high-activity mutants of human butyrylcholinesterase.

Authors:  Shurong Hou; Liu Xue; Wenchao Yang; Lei Fang; Fang Zheng; Chang-Guo Zhan
Journal:  Org Biomol Chem       Date:  2013-11-21       Impact factor: 3.876

2.  Distinct localization of collagen Q and PRiMA forms of acetylcholinesterase at the neuromuscular junction.

Authors:  Véronique Bernard; Emmanuelle Girard; Anna Hrabovska; Shelley Camp; Palmer Taylor; Benoit Plaud; Eric Krejci
Journal:  Mol Cell Neurosci       Date:  2010-09-29       Impact factor: 4.314

3.  Identification of neuromuscular junctions by correlative confocal and transmission electron microscopy.

Authors:  Shannon Modla; Janet Mendonca; Kirk J Czymmek; Robert E Akins
Journal:  J Neurosci Methods       Date:  2010-06-25       Impact factor: 2.390

4.  Localization of butyrylcholinesterase at the neuromuscular junction of normal and acetylcholinesterase knockout mice.

Authors:  Brigitte Blondet; Gilles Carpentier; Arnaud Ferry; Arnaud Chatonnet; José Courty
Journal:  J Histochem Cytochem       Date:  2010-08-30       Impact factor: 2.479

Review 5.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

6.  Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan K LeBrasseur; Thomas A White; Robin J Parks; Stephen Brimijoin
Journal:  Vaccine       Date:  2014-06-02       Impact factor: 3.641

7.  Acetylcholinesterase mobility and stability at the neuromuscular junction of living mice.

Authors:  Isabel Martinez-Pena y Valenzuela; Mohammed Akaaboune
Journal:  Mol Biol Cell       Date:  2007-05-30       Impact factor: 4.138

8.  Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan LeBrasseur; Thomas White; Stephen Brimijoin
Journal:  J Mol Neurosci       Date:  2013-10-02       Impact factor: 3.444

9.  Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity.

Authors:  Liyi Geng; Yang Gao; Xiabin Chen; Shurong Hou; Chang-Guo Zhan; Zoran Radic; Robin J Parks; Stephen J Russell; Linh Pham; Stephen Brimijoin
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

10.  MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.

Authors:  Annie Cartaud; Laure Strochlic; Manuel Guerra; Benoît Blanchard; Monique Lambergeon; Eric Krejci; Jean Cartaud; Claire Legay
Journal:  J Cell Biol       Date:  2004-05-24       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.